<DOC>
	<DOC>NCT01230125</DOC>
	<brief_summary>The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.</brief_summary>
	<brief_title>Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<criteria>Participants who are candidates for routine, uncomplicated cataract surgery Participants who, in the Investigator's opinion, have potential postoperative pinhole Snellen visual acuity (VA) of at least 20/200 in the study eye. Participants must be willing to wait to undergo cataract surgery on the fellow eye until after the study has been completed. Participants who are expected to require concurrent ocular therapy (either eye) with nonsteroidal antiinflammatory drugs (NSAIDs), mast cell stabilizers, antihistamines, or decongestants. Participants who are expected to require treatment with any systemic or ocular (either eye) corticosteroids or glucocorticoids. Participants who are expected to require concurrent ocular therapy with immunosuppressants (eg, Restasis). Participants who have known hypersensitivity or contraindication to the study drug(s) or their components. Participants participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Pain</keyword>
	<keyword>Ocular surgery</keyword>
</DOC>